Cheshire drug maker Alexion Pharmaceuticals Inc. said today an advisory panel in Europe recommended commissioning of the company’s Smithfield, R.I. manufacturing facility.
The company is hoping to use the facility as a second source of supply for the blood disorder treatment Soliris.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive recommendation and the European agency will take that into consideration. Alexion expects a decision in early 2010.
Meanwhile, the company expects to meet with the Food and Drug Administration to discuss steps to approval. (AP)
